These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28731125)

  • 1. N-peptide of vMIP-Ⅱ reverses paclitaxel-resistance by regulating miRNA-335 in breast cancer.
    Wang Y; Wang H; Ding Y; Li Y; Chen S; Zhang L; Wu H; Zhou J; Duan K; Wang W; Chen C; Yang Q
    Int J Oncol; 2017 Sep; 51(3):918-930. PubMed ID: 28731125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.
    Wang Y; Yan L; Zhang L; Xu H; Chen T; Li Y; Wang H; Chen S; Wang W; Chen C; Yang Q
    Int J Oncol; 2018 Sep; 53(3):1043-1054. PubMed ID: 30015868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The N-terminal polypeptide derived from viral macrophage inflammatory protein II reverses breast cancer epithelial-to-mesenchymal transition via a PDGFRα-dependent mechanism.
    Yang QL; Zhang LY; Wang HF; Li Y; Wang YY; Chen TT; Dai MF; Wu HH; Chen SL; Wang WR; Wu Q; Chen CJ; Zhou CZ
    Oncotarget; 2017 Jun; 8(23):37448-37463. PubMed ID: 28415580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer.
    Wang W; Zhang L; Wang Y; Ding Y; Chen T; Wang Y; Wang H; Li Y; Duan K; Chen S; Yang Q; Chen C
    Cell Death Dis; 2017 Oct; 8(10):e3071. PubMed ID: 28981108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-155-5p promotes tumor progression and contributes to paclitaxel resistance via TP53INP1 in human breast cancer.
    Li Y; Zhang L; Dong Z; Xu H; Yan L; Wang W; Yang Q; Chen C
    Pathol Res Pract; 2021 Apr; 220():153405. PubMed ID: 33756128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of miRNA-21 on paclitaxel-resistance in human breast cancer cells].
    Zhao ZL; Cai Y; Wang YY; Xia CL; Li CX; Chen SL; Yang QL; Chen CJ
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2015 Jul; 44(4):400-9. PubMed ID: 26555418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumour activity of the recombination polypeptide GST-NT21MP is mediated by inhibition of CXCR4 pathway in breast cancer.
    Yang Q; Zhang F; Ding Y; Huang J; Chen S; Wu Q; Wang Z; Wang Z; Chen C
    Br J Cancer; 2014 Mar; 110(5):1288-97. PubMed ID: 24448360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [miR-16-5p regulates apoptosis and migration of drug-resistant breast cancer cells by targeting YWHAQ].
    Zhu H; Mao H; Tao S; Wang W; Chen C; Yang Q
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Oct; 42(10):1476-1485. PubMed ID: 36329581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.
    Yang Q; Wang Y; Lu X; Zhao Z; Zhu L; Chen S; Wu Q; Chen C; Wang Z
    Oncotarget; 2015 Feb; 6(5):3268-79. PubMed ID: 25605244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of SPIN1-mediated PI3K-Akt pathway by miR-489 increases chemosensitivity in breast cancer.
    Chen X; Wang YW; Xing AY; Xiang S; Shi DB; Liu L; Li YX; Gao P
    J Pathol; 2016 Aug; 239(4):459-72. PubMed ID: 27171498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of miR‑200c‑3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2.
    Chen J; Tian W; He H; Chen F; Huang J; Wang X; Chen Z
    Oncol Rep; 2018 Dec; 40(6):3821-3829. PubMed ID: 30272330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-494 suppresses the progression of breast cancer in vitro by targeting CXCR4 through the Wnt/β-catenin signaling pathway.
    Song L; Liu D; Wang B; He J; Zhang S; Dai Z; Ma X; Wang X
    Oncol Rep; 2015 Jul; 34(1):525-31. PubMed ID: 25955111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Knockdown of nuclear receptor binding SET domain-containing protein 1 (NSD1) inhibits proliferation and facilitates apoptosis in paclitaxel-resistant breast cancer cells via inactivating the Wnt/β-catenin signaling pathway.
    Chen Y; Li X; Xu J; Xiao H; Tang C; Liang W; Zhu X; Fang Y; Wang H; Shi J
    Bioengineered; 2022 Feb; 13(2):3526-3536. PubMed ID: 35200072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
    Kastl L; Brown I; Schofield AC
    Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4.
    Xue Y; Xu W; Zhao W; Wang W; Zhang D; Wu P
    Biomed Pharmacother; 2017 Feb; 86():426-433. PubMed ID: 28012397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA‑335 inhibits bladder cancer cell growth and migration by targeting mitogen‑activated protein kinase 1.
    Wang X; Wu G; Cao G; Chen X; Huang J; Jiang X; Hou J
    Mol Med Rep; 2016 Aug; 14(2):1765-70. PubMed ID: 27356628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
    Shen H; Wang D; Li L; Yang S; Chen X; Zhou S; Zhong S; Zhao J; Tang J
    Gene; 2017 Jan; 596():110-118. PubMed ID: 27746366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
    Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The N-terminal polypeptide derived from vMIP-II exerts its antitumor activity in human breast cancer through CXCR4/miR-7-5p/Skp2 pathway.
    Wang HF; Dong ZY; Yan L; Yang S; Xu HN; Chen SL; Wang WR; Yang QL; Chen CJ
    J Cell Physiol; 2020 Dec; 235(12):9474-9486. PubMed ID: 32372405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.